Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. Sars, Structural Analysis, and Biological Characterization Publisher Pubmed



Butini S1 ; Grether U2 ; Jung KM3 ; Ligresti A4 ; Allara M4 ; Postmus AGJ5 ; Maramai S1 ; Brogi S6 ; Papa A1 ; Carullo G1 ; Sykes D7, 8 ; Veprintsev D7 ; Federico S1 ; Grillo A1 Show All Authors
Authors
  1. Butini S1
  2. Grether U2
  3. Jung KM3
  4. Ligresti A4
  5. Allara M4
  6. Postmus AGJ5
  7. Maramai S1
  8. Brogi S6
  9. Papa A1
  10. Carullo G1
  11. Sykes D7, 8
  12. Veprintsev D7
  13. Federico S1
  14. Grillo A1
  15. Di Guglielmo B1
  16. Ramunno A9
  17. Stevens AF5
  18. Heer D2
  19. Lamponi S1
  20. Gemma S1
  21. Benz J2
  22. Di Marzo V4, 10, 11, 12, 13
  23. Van Der Stelt M5
  24. Piomelli D3
  25. Campiani G1, 14
Show Affiliations
Authors Affiliations
  1. 1. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, via Aldo Moro 2, Siena, 53100, Italy
  2. 2. Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland
  3. 3. Department of Anatomy and Neurobiology, University of California Irvine, Irvine, 92697, CA, United States
  4. 4. Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, Pozzuoli, 80078, Italy
  5. 5. Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University and Oncode Institute, Leiden, 2300 CC, Netherlands
  6. 6. Department of Pharmacy, University of Pisa, via Bonanno, Pisa, 56126, Italy
  7. 7. Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, NG7 2UH, United Kingdom
  8. 8. Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, University of Nottingham, Edgbaston, Midlands, Birmingham, B15 2TT, United Kingdom
  9. 9. Department of Pharmacy/DIFARMA, University of Salerno, via Giovanni Paolo II 132, Fisciano, Salerno, 84084, Italy
  10. 10. Centre Nutrition, Sante et Societe (NUTRISS), Institut sur La Nutrition Et Les Aliments Fonctionnels (INAF), Ecole de Nutrition, Universite Laval, 2440 Boulevard Hochelaga, Quebec, G1V 0A6, Canada
  11. 11. Canada Excellence Research Chair in the Microbiome-Endocannabinoidome Axis in Metabolic Health, Quebec, G1V 0A6, Canada
  12. 12. Centre de Recherche de l’Institut de Cardiologie et de Pneumologie de Quebec, Faculte de Medecine, Departement de Medecine, Universite Laval, PO Box 2725, Quebec, G1V 4G5, Canada
  13. 13. Unite Mixte Internationale en Recherche Chimique et Biomoleculaire sur le Microbiome et Son Impact Sur la Sante Metabolique et la Nutrition (UMI-MicroMeNu), Universite Laval, Quebec, G1V 0A6, Canada
  14. 14. Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, 81746-7346, Iran

Source: Journal of Medicinal Chemistry Published:2024


Abstract

New potent, selective monoacylglycerol lipase (MAGL) inhibitors based on the azetidin-2-one scaffold ((±)-5a-v, (±)-6a-j, and (±)-7a-d) were developed as irreversible ligands, as demonstrated by enzymatic and crystallographic studies for (±)-5d, (±)-5l, and (±)-5r. X-ray analyses combined with extensive computational studies allowed us to clarify the binding mode of the compounds. 5v was identified as selective for MAGL when compared with other serine hydrolases. Solubility, in vitro metabolic stability, cytotoxicity, and absence of mutagenicity were determined for selected analogues. The most promising compounds ((±)-5c, (±)-5d, and (±)-5v) were used for in vivo studies in mice, showing a decrease in MAGL activity and increased 2-arachidonoyl-sn-glycerol levels in forebrain tissue. In particular, 5v is characterized by a high eudysmic ratio and (3R,4S)-5v is one of the most potent irreversible inhibitors of h/mMAGL identified thus far. These results suggest that the new MAGL inhibitors have therapeutic potential for different central and peripheral pathologies. © 2024 American Chemical Society.